immunological impact of tp53 in mds
Published 3 years ago • 141 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
2:49
the role of the immune system in the pathophysiology of mds
-
2:06
understanding the role of inflammation and the immunome in mds pathophysiology
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
1:13
targeting p53 in mds
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
2:43
tim wassenaar, md, hematologist
-
9:01
what are moyamoya blood vessels? explained by a pain treatment specialist
-
4:28
understanding myelodysplastic syndromes (mds)
-
1:41
an overview of the mds diagnosis pathway
-
1:36
the impact of tp53 mutations in patients with myelofibrosis undergoing sct
-
9:41
the i4mds consortium and immune monitoring in mds
-
2:10
using the innate immune system to treat mds & the value of novel immunotherapies
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
2:24
the challenges of treating tp53-mutated aml and mds
-
1:53
immuno-oncology paving the way in mds
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
3:00
apr-246 in tp53 mutated mds and aml
-
4:27
the role of immune checkpoint inhibitors in mds
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
4:44
immunotherapy in mds